Consolidated figures · ₹ crore
| ₹ Cr | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| 1,153 | 1,052 | 723 | 719 | 739 | |
| COGS | 775 | 688 | 489 | 457 | 437 |
| Gross profit | 378 | 363 | 234 | 262 | 301 |
| 173 | 199 | 198 | 209 | 214 | |
| 205 | 164 | 37 | 53 | 87 | |
| OPM % | 17.8% | 15.6% | 5.1% | 7.4% | 11.8% |
| Depreciation | 30 | 29 | 35 | 36 | 40 |
| Interest | 6 | 11 | 16 | 24 | 18 |
| 7 | 13 | 6 | 9 | 13 | |
| Profit before tax | 176 | 137 | -9 | 2 | 42 |
| Tax | 48 | 35 | -0 | 6 | 9 |
| Tax % | 27.4% | 25.2% | -3.5% | 259.5% | 20.8% |
| 128 | 103 | -8 | -3 | 33 | |
| PAT margin % | 11.1% | 9.8% | -1.2% | -0.5% | 4.5% |
| EPS (₹) | 41.7 | 32.5 | -3.1 | -1.2 | 11.9 |
| EPS adjusted (₹) | 41.7 | 32 | -3 | -1.3 | 11.9 |
| 8.4% | 3.1% | — | — | — | |
| Annual report | Annual report for Mar 2022 | Annual report for Mar 2023 | Annual report for Mar 2024 | Annual report for Mar 2025 | — |
| ₹ Cr | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 27 | 27 | 28 | 28 | 28 | 28 |
| Reserves | 475 | 586 | 662 | 702 | 697 | 731 |
| Minority interest | 7 | 36 | 51 | — | — | — |
| 208 | 363 | 274 | 256 | 248 | 253 | |
| 160 | 181 | 226 | 262 | 209 | 219 | |
| Total equity & liabilities | 876 | 1,192 | 1,239 | 1,248 | 1,183 | 1,231 |
| 497 | 530 | 670 | 643 | 657 | 695 | |
| CWIP | 46 | 112 | 71 | 86 | 66 | 21 |
| Investments | 6 | 8 | 41 | 99 | 94 | 151 |
| 327 | 542 | 457 | 420 | 367 | 364 | |
| Total assets | 876 | 1,192 | 1,239 | 1,248 | 1,183 | 1,231 |
As reported in NSE results XBRL. Segment result is before tax and finance costs. ROCE uses that annual result divided by segment assets less liabilities.
Latest reported period · 31 Mar 2026 · ₹ crore
| Segment | Revenue | Result | Assets | Liabilities | Capital employed | ROCE % |
|---|---|---|---|---|---|---|
| Speciality Chemical Division | 574.82 | 60.25 | 670.59 | 265.6 | 404.99 | 14.88 |
| Pharma Division | 163.94 | -5.84 |
| ₹ Cr | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|
| 76 | 161 | 115 | -32 | 238 | 84 | 56 | 92 | |
| -88 | -184 | -159 | -122 | -143 | -65 | -21 | -86 | |
| 1 | 27 | 49 | 167 | -112 | -23 | -32 | -11 | |
| Net cash flow | -11 | 5 | 5 | 12 | -17 | -4 | 4 | -5 |
| Free cash flow | — | -44 | -56 | -153 | 102 | 10 | 26 | 58 |
| CFO / Operating profit % | — | — | — | -15.9% | 144.9% | 219.7% | 105.1% | 104.3% |
| 558.41 |
| 219.54 |
| 338.87 |
| -1.72 |
₹ crore by fiscal year